Xofigo® Prostate Cancer Treatment

Cancer spreads to the bone in 90% of men with advanced prostate cancer.
Xofigo® (radium Ra 223 dichloride) injection is used to treat prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has spread to your bones with symptoms, but not to other parts of your body. The medical term for this condition is metastatic castration-resistant prostate cancer, or mCRPC.

How Does Xofigo® Treatment Work?

  • Is an injection used to treat prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has spread to your bones with symptoms, but not to other parts of your body. The medical term for this condition is metastatic castration-resistant prostate cancer,or mCRPC
  • Helps extend life by more than 30% (14.9 months in Xofigo-treated men vs 11.3 months in placebo-treated men, in an updated analysis)
  • Goes to the bone, giving off strong energy that helps kill cancer cells, but does limited damage to nearby healthy cells
  • Can be absorbed by organs other than bone, primarily the bone marrow and digestive system, which can result in side e ects in those healthy tissues

What Is Xofigo® Used for?

Xofigo (zo-FEEG-oh) is an intravenous (IV) injection of the radioactive material radium 223. It is used to treat prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has spread to your bones with symptoms, but not to other parts of your body. The medical term for this condition is metastatic castration-resistant prostate cancer, or mCRPC.